Company Filing History:
Years Active: 2008
Title: The Innovations of Laurent Naudin
Introduction
Laurent Naudin is a notable inventor based in Etampes, France. He has made significant contributions to the field of biotechnology, particularly in the regulation of genes associated with cholesterol metabolism.
Latest Patents
Naudin holds a patent for a regulatory nucleic acid for the ABC1 gene, which is crucial in addressing pathologies linked to cholesterol metabolism dysfunction. This invention involves a nucleic acid capable of regulating the transcription of the ABC1 gene, which is known to induce diseases such as atherosclerosis. The patent also encompasses nucleotide constructs that include a polynucleotide encoding a polypeptide or a nucleic acid of interest, controlled by the regulatory nucleic acid for the ABC1 gene. Furthermore, it relates to recombinant vectors, transformed host cells, and nonhuman transgenic mammals that incorporate this regulatory nucleic acid or the aforementioned nucleotide construct. Methods for screening molecules that can modify the activity of the regulatory nucleic acid for the ABC1 gene are also part of this innovative work.
Career Highlights
Laurent Naudin is currently associated with Aventis Pharma S.A., where he continues to advance his research and development efforts. His work has been instrumental in exploring therapeutic uses for his inventions, contributing to the understanding of cholesterol-related diseases.
Collaborations
Naudin has collaborated with esteemed colleagues such as Marie-Françoise Rosier-Montus and Catherine Prades. Their combined expertise has further enhanced the impact of his research in the field.
Conclusion
Laurent Naudin's innovative work in gene regulation and cholesterol metabolism highlights the importance of biotechnology in addressing critical health issues. His contributions continue to pave the way for future advancements in therapeutic applications.